The deal encompasses WoundSkan, a temperature-sensing smart dressing, and the Spektra Lateral Flow Test, a multi-marker screening platform. Davion leadership maintains that both assets fit their strategic focus on battery-free, smartphone-integrated health monitoring. This acquisition represents the company's first major move since its direct listing on the Nasdaq Global Market just last week.
In section Market Quotes
Davion Healthcare Shares Plunge After $25 Million IP Buyout
Investors wiped 19% off Davion Healthcare’s market value on Monday, driving the stock down to $4.85 in premarket trading. The sharp decline followed the company’s announcement that it had spent $25 million in cash and equity to acquire intellectual property for two medical diagnostic technologies from Humaskan shareholders.
To fund the purchase, Davion paid $2.5 million in cash and issued approximately 1.7 million new ordinary shares. The stock portion of the deal was valued at a fixed contractual price of $13 per share, totaling $22.5 million. Chief Executive Glenn Williams stated the firm is now positioned to accelerate the development and commercialization of these technologies while scouting for additional growth opportunities.
Comments (0)
No comments yet. Be the first!